NASDAQ:GENE - Genetic Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.68 -0.02 (-2.85 %) (As of 05/26/2019 03:18 PM ET)Previous Close$0.6823Today's Range$0.6502 - $0.698952-Week Range$0.51 - $2.04Volume425,885 shsAverage Volume643,325 shsMarket Capitalization$11.08 millionP/E RatioN/ADividend YieldN/ABeta3.85 ProfileChartFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia. Receive GENE News and Ratings via Email Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GENE Previous Symbol CUSIPN/A CIK1166272 Webhttp://www.gtglabs.com/ Phone61-3-8412-7000Debt Debt-to-Equity RatioN/A Current Ratio3.99 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales79.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book3.10Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares16,235,000Market Cap$11.08 million Next Earnings DateN/A OptionableOptionable Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions What is Genetic Technologies' stock symbol? Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE." Has Genetic Technologies been receiving favorable news coverage? Media headlines about GENE stock have been trending negative on Sunday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genetic Technologies earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the immediate future. Who are some of Genetic Technologies' key competitors? Some companies that are related to Genetic Technologies include Pharmacyte Biotech (PMCB), BioCardia (BCDA), BIONDVAX PHARMA/S (BVXV), Entera Bio (ENTX), Outlook Therapeutics (OTLK), Vical (VICL), Microbot Medical (MBOT), TRACON Pharmaceuticals (TCON), aTyr Pharma (LIFE), CytRx (CYTR), Titan Pharmaceuticals (TTNP), Windtree Therapeutics (WINT), TrovaGene (TROV), Aevi Genomic Medicine (GNMX) and Mymetics (MYMX). What other stocks do shareholders of Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Novavax (NVAX), Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Microbot Medical (MBOT), Sophiris Bio (SPHS), SLS International (SLS), Akari Therapeutics (AKTX), Athersys (ATHX), Antares Pharma (ATRS) and Cyclacel Pharmaceuticals (CYCC). Who are Genetic Technologies' key executives? Genetic Technologies' management team includes the folowing people: Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. DirectorMr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec. Who are Genetic Technologies' major shareholders? Genetic Technologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.45%) and Alpine Group USVI LLC (0.18%). Which institutional investors are selling Genetic Technologies stock? GENE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Which institutional investors are buying Genetic Technologies stock? GENE stock was purchased by a variety of institutional investors in the last quarter, including Alpine Group USVI LLC. How do I buy shares of Genetic Technologies? Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Genetic Technologies' stock price today? One share of GENE stock can currently be purchased for approximately $0.6823. How big of a company is Genetic Technologies? Genetic Technologies has a market capitalization of $11.08 million and generates $140,000.00 in revenue each year. What is Genetic Technologies' official website? The official website for Genetic Technologies is http://www.gtglabs.com/. How can I contact Genetic Technologies? Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 61-3-8412-7000 or via email at [email protected] MarketBeat Community Rating for Genetic Technologies (NASDAQ GENE)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 98 (Vote Outperform)Underperform Votes: 130 (Vote Underperform)Total Votes: 228MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe GENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What is a good rate of return for a mutual fund? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.